A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Status:
RECRUITING
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma.
The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.